Zepbound and Wegovy are different weight-management drugs. Zepbound contains tirzepatide and is made by Eli Lilly and Company, while Wegovy contains semaglutide and is made by Novo Nordisk.1,2 In a direct 72-week trial of adults with obesity without type 2 diabetes, tirzepatide led to greater average weight loss than semaglutide.3 Your physician still needs to weigh your medical history, treatment goals, and tolerance before choosing between them.
Zepbound vs Wegovy Comparison
Both drugs are approved for chronic weight management, but they use different molecules and have different full indication lists.1,2 Zepbound activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Wegovy activates GLP-1 receptors.
The mechanism difference can affect weight response and tolerability. It does not tell your physician which drug fits your health history on its own. For a deeper explanation of the two molecules, see semaglutide vs tirzepatide.
| Brand | Active Ingredient | Manufacturer | Mechanism | U.S. Food and Drug Administration (FDA)-Approved Indication(s) |
|---|---|---|---|---|
| Zepbound | Tirzepatide | Eli Lilly and Company | Dual GIP and GLP-1 receptor agonist | Long-term weight reduction in adults with obesity, or adults with overweight and at least one weight-related condition. Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.1 |
| Wegovy | Semaglutide | Novo Nordisk | GLP-1 receptor agonist | Long-term weight reduction in adults and adolescents aged 12 years and older with obesity, and adults with overweight and at least one weight-related condition. Reduction of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis in adults under accelerated approval.2 |
These indication lists can change the choice. If obstructive sleep apnea is part of your treatment goal, Zepbound has an indication for that population. If you have established cardiovascular disease or qualifying liver disease, Wegovy has indications that directly address those conditions.1,2
Zepbound and Mounjaro contain the same active ingredient under different indications. That pairing is covered in Zepbound vs Mounjaro. Wegovy and Ozempic both contain semaglutide, which is covered in Ozempic vs Wegovy.
The Head-to-Head Weight Loss Result
SURMOUNT-5 directly compared tirzepatide with semaglutide in 751 adults with obesity who did not have type 2 diabetes.3 The trial was randomized and open-label, which means participants and investigators knew which treatment was assigned. Each drug was used at its own maximum tolerated dose for 72 weeks.
Average body weight changed by minus 20.2% with tirzepatide and minus 13.7% with semaglutide at week 72.3 Average waist circumference decreased by 18.4 centimeters with tirzepatide and 13.0 centimeters with semaglutide.3
This is stronger comparative evidence than placing results from two separate trials side by side. Separate studies can differ in their participants, treatment periods, endpoints, and study procedures. SURMOUNT-5 assigned both treatments within one trial and evaluated them over the same period.
For the population studied, tirzepatide produced greater average weight loss. That is the clearest evidence-based answer to the Zepbound vs Wegovy weight-loss question. It remains an average from one trial. Your response can fall above or below either average, and the trial does not predict which drug you will tolerate better.
The Population Covered by SURMOUNT-5
SURMOUNT-5 answers a defined question about adults with obesity who did not have type 2 diabetes.3 It does not provide a general ranking for every person who may qualify for Zepbound or Wegovy.
Several groups fall outside the trial population or its main comparison:
- People with type 2 diabetes: SURMOUNT-5 excluded adults with type 2 diabetes. Its average weight changes should not be presented as results for that population.
- Adolescents: Wegovy is approved for chronic weight management in adolescents aged 12 years and older with obesity, but SURMOUNT-5 studied adults.2,3
- People considering a switch: SURMOUNT-5 was a treatment comparison. It did not test a switching protocol for people already established on Wegovy or Zepbound.
- People being treated for obstructive sleep apnea: Zepbound has a separate indication for moderate-to-severe obstructive sleep apnea in adults with obesity.1 SURMOUNT-5 did not establish comparative outcomes for that indication.
- People with established cardiovascular disease or qualifying liver disease: Wegovy has separate indications for cardiovascular-risk reduction and treatment of qualifying metabolic dysfunction-associated steatohepatitis (MASH).2 SURMOUNT-5 did not compare the drugs for those outcomes.
The trial also does not answer questions about insurance coverage or out-of-pocket expense. Those details can affect access even when a physician prefers one treatment. Our GLP-1 cost guide explains the line items to compare without turning this clinical comparison into a pricing estimate.
If your health picture falls outside the SURMOUNT-5 population, your physician should give the trial appropriate weight while using evidence that matches your condition. The headline percentage becomes one input in a broader prescribing decision.
Approved Uses That Can Change the Choice
The complete indication list may carry more weight than average weight loss when you have another condition covered by one label. Zepbound and Wegovy overlap in chronic weight management, but their other approved uses differ.1,2
Zepbound is approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.1 Obstructive sleep apnea causes repeated breathing interruptions during sleep. If OSA is part of your diagnosis, your physician can assess Zepbound within that approved use.
Wegovy is approved to reduce the risk of major cardiovascular events in adults who have established cardiovascular disease and either obesity or overweight.2 It is also approved for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis under accelerated approval.2 MASH is a form of liver disease involving fat buildup, inflammation, and liver-cell injury.
Wegovy’s chronic weight-management indication also includes adolescents aged 12 years and older with obesity.2 Zepbound’s weight-management indication in the current label covers adults.1
These differences do not create a universal winner. They give your physician a more specific basis for the choice when sleep apnea, cardiovascular disease, liver disease, or age is part of your treatment decision.
Tolerability and Label Safety Information
Tolerability can determine whether you can stay on either treatment long enough for it to help. SURMOUNT-5 does not support a general claim that one drug has a better side-effect profile for every person.
Wegovy’s current label lists nausea, diarrhea, vomiting, constipation, and abdominal pain among common adverse reactions. It also lists dysesthesia, headache, and fatigue among reactions occurring in at least 5% of adults or adolescents aged 12 years and older.2 Zepbound and Wegovy both include GLP-1 receptor activity, so gastrointestinal tolerance belongs in the prescribing conversation. The available sources do not support treating the two drugs’ adverse-reaction percentages as interchangeable.
Each label also carries a thyroid C-cell tumor warning, but the wording should be read separately. The Zepbound label states that tirzepatide causes thyroid C-cell tumors in rats and that the human risk is unknown.1 The Wegovy label states that semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents, with human risk also unknown.2
Both labels contraindicate treatment if you have a personal or family history of medullary thyroid carcinoma (MTC). The same contraindication applies if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).1,2 Your physician needs that history before prescribing either drug.
A Physician’s Decision Framework
A direct comparison starts with the trial result, then moves to your health history. Your physician may weigh several factors:
- Whether your diagnosis matches the populations covered by either label
- Whether OSA, cardiovascular disease, or MASH changes the treatment goal
- Your personal and family thyroid-cancer history
- Your gastrointestinal tolerance and response to previous treatment
- Whether you take another tirzepatide-containing product or a GLP-1 receptor agonist
The Zepbound label does not recommend using Zepbound with another tirzepatide-containing product or another GLP-1 receptor agonist.1 This becomes relevant if you already use a drug in either category. Your prescriber needs a complete medication list before making a change.
Access can also affect the decision, but this page does not rank the drugs by price or insurance coverage. Those figures vary and are outside the comparative clinical evidence provided here. Your physician can identify the clinically appropriate options before you verify coverage for the prescribed product.
The Opt Take on Zepbound and Wegovy
We start with an initial panel of 55+ biomarkers, followed by a one-on-one review with an Opt Health physician. The physician reads those results alongside your symptoms, current medications, medical history, and goals.
The average weight-loss percentage from SURMOUNT-5 is one data point. Your thyroid-risk history, cardiovascular markers, gastrointestinal tolerance, and diagnoses add the context needed to use that result. Zepbound’s OSA indication may fit one health picture, while Wegovy’s cardiovascular-risk or MASH indications may fit another.1,2
We repeat labs and a physician consultation every three to four months. Your plan can then be adjusted based on what your biomarkers, symptoms, and treatment response show over time. The process continues through testing, physician interpretation, treatment, retesting, and adjustment.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Zepbound produced greater average weight loss than Wegovy in SURMOUNT-5, but that finding does not make Zepbound better for every person. In adults with obesity without type 2 diabetes, average weight changed by minus 20.2% with tirzepatide and minus 13.7% with semaglutide at week 72.3
The trial did not rank the drugs for every side effect, approved condition, or individual response. It also did not cover adolescents, people with type 2 diabetes, Zepbound’s separate OSA population, or Wegovy’s cardiovascular-risk and MASH populations. Your physician should match the evidence and approved uses to your health history.
Zepbound contains tirzepatide and activates both GIP and GLP-1 receptors. Wegovy contains semaglutide and activates GLP-1 receptors.1,2 The drugs are made by different manufacturers and carry different complete indication lists.
Both cover chronic weight management in qualifying adults. Zepbound also covers moderate-to-severe OSA in adults with obesity.1 Wegovy also covers qualifying adolescents, cardiovascular-risk reduction in certain adults, and qualifying noncirrhotic MASH under accelerated approval.2
“Stronger” is not a validated clinical ranking for these two drugs. Their milligram amounts cannot be used as a potency comparison because tirzepatide and semaglutide are different molecules.
SURMOUNT-5 found greater average weight loss with tirzepatide than with semaglutide over 72 weeks in adults with obesity without type 2 diabetes.3 That result does not establish broader superiority for side effects, other approved conditions, access, or your individual response.
Switching from Wegovy to Zepbound is a prescribing decision based on your medical history, tolerance, medication list, and response. The available sources do not establish a switching protocol, and SURMOUNT-5 did not study how to move people from one drug to the other.
Your prescriber should decide whether a change is appropriate and manage the transition. Bring your treatment response, adverse effects, current medications, and goals to that discussion when comparing Zepbound vs Wegovy.
References
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use: full prescribing information. DailyMed. Revised August 2026. Accessed November 2, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Novo Nordisk. WEGOVY (semaglutide) injection, solution: full prescribing information. DailyMed. Revised June 2026. Accessed November 2, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
This article is part of our guide to weight loss. See the doctor-guided weight loss program at Opt Health.
You might also like
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.